As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Pyxis Oncology, Inc. The largest reported stake is GordonMD Global Investments LP's, at 16.4%. 11 filings are on record since July 1, 2025 (Schedule 13G/A, October 9, 2026).
Sell to companies like Pyxis Oncology, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Laurion Capital Management LP · Sole voting: 0 · Shared voting: 4,300,888 · Sole dispositive: 0 · Shared dispositive: 4,300,888 · SCHEDULE 13G/A, 2026-11-03
- · Reporting person: GordonMD Global Investments LP · Sole voting: 0 · Shared voting: 20,441,948 · Sole dispositive: 0 · Shared dispositive: 20,441,948 · SCHEDULE 13G/A, 2026-10-09
- · Reporting person: Coastlands Capital LP · Sole voting: 0 · Shared voting: 6,448,907 · Sole dispositive: 0 · Shared dispositive: 6,448,907 · SCHEDULE 13G, 2026-10-05
- · Holder: GordonMD Global Investments LP · Percent: 17.5% · SCHEDULE 13G/A
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 4,611,887 · Sole dispositive: 0 · Shared dispositive: 4,611,887 · SCHEDULE 13G, 2026-07-10
Pyxis Oncology, Inc. has 11 Schedule 13D or 13G filings on record since 2025-07-01. 4 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| GordonMD Global Investments LP | 16.4% | 20,441,948 | SCHEDULE 13G/A, 2026-10-09 | 2026-10-01 |
| Bvf Partners L P | 9.99% | 8,336,902 | SCHEDULE 13G, 2026-07-10 | 2026-07-02 |
| Coastlands Capital LP | 5.42% | 6,448,907 | SCHEDULE 13G, 2026-10-05 | 2026-10-01 |
| Laurion Capital Management LP | 5.16% | 4,300,888 | SCHEDULE 13G/A, 2026-11-03 | 2026-09-30 |
| BlackRock, Inc. | 1.5% | 926,805 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
| Millennium Management LLC | 1.3% | 818,134 | SCHEDULE 13G/A, 2025-10-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Pyxis Oncology, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Pyxis Oncology, Inc. and the records around it.
Pyxis Oncology, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- GordonMD Global Investments LP also filed stake reports on 1 other company: Kyverna Therapeutics, Inc. (Nov 2025)
- Laurion Capital Management LP also filed stake reports on 2 other companies: IMMUNIC, INC. (Aug 2026), Rallybio Corp (Aug 2026)
- Coastlands Capital LP also filed stake reports on 16 other companies: Sutro Biopharma, Inc. (Nov 2026), Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026)
Watch Pyxis Oncology, Inc.
Get an email when Pyxis Oncology, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pyxis Oncology, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Pyxis Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pyxis Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 0 | 20,441,948 | 0 | 20,441,948 | SCHEDULE 13G/A, 2026-10-09 |
| GordonMD Long Biased Master Fund LP | 0 | 20,441,948 | 0 | 20,441,948 | SCHEDULE 13G/A, 2026-10-09 |
| GordonMD Long Biased GP LLC | 0 | 20,441,948 | 0 | 20,441,948 | SCHEDULE 13G/A, 2026-10-09 |
| Craig D. Gordon | 0 | 20,441,948 | 0 | 20,441,948 | SCHEDULE 13G/A, 2026-10-09 |
| Biotechnology Value Fund L P | 0 | 4,611,887 | 0 | 4,611,887 | SCHEDULE 13G, 2026-07-10 |
| Bvf I Gp LLC | 0 | 4,611,887 | 0 | 4,611,887 | SCHEDULE 13G, 2026-07-10 |
| Biotechnology Value Fund Ii LP | 0 | 3,083,847 | 0 | 3,083,847 | SCHEDULE 13G, 2026-07-10 |
| Bvf Ii Gp LLC | 0 | 3,083,847 | 0 | 3,083,847 | SCHEDULE 13G, 2026-07-10 |
| Biotechnology Value Trading Fund OS LP | 0 | 518,280 | 0 | 518,280 | SCHEDULE 13G, 2026-07-10 |
| BVF Partners OS Ltd. | 0 | 518,280 | 0 | 518,280 | SCHEDULE 13G, 2026-07-10 |
| Bvf Gp Holdings LLC | 0 | 7,695,734 | 0 | 7,695,734 | SCHEDULE 13G, 2026-07-10 |
| Bvf Partners L P | 0 | 8,336,902 | 0 | 8,336,902 | SCHEDULE 13G, 2026-07-10 |
| Bvf Inc | 0 | 8,336,902 | 0 | 8,336,902 | SCHEDULE 13G, 2026-07-10 |
| Lampert Mark N | 0 | 8,336,902 | 0 | 8,336,902 | SCHEDULE 13G, 2026-07-10 |
| Coastlands Capital LP | 0 | 6,448,907 | 0 | 6,448,907 | SCHEDULE 13G, 2026-10-05 |
| Coastlands Capital Partners LP | 0 | 6,448,907 | 0 | 6,448,907 | SCHEDULE 13G, 2026-10-05 |
| Coastlands Capital GP LLC | 0 | 6,448,907 | 0 | 6,448,907 | SCHEDULE 13G, 2026-10-05 |
| Coastlands Capital LLC | 0 | 6,448,907 | 0 | 6,448,907 | SCHEDULE 13G, 2026-10-05 |
| Matthew D. Perry | 0 | 6,448,907 | 0 | 6,448,907 | SCHEDULE 13G, 2026-10-05 |
| Laurion Capital Management LP | 0 | 4,300,888 | 0 | 4,300,888 | SCHEDULE 13G/A, 2026-11-03 |
| Benjamin Alexander Smith | 0 | 4,300,888 | 0 | 4,300,888 | SCHEDULE 13G/A, 2026-11-03 |
| Janaka Sheehan Maduraperuma | 0 | 4,300,888 | 0 | 4,300,888 | SCHEDULE 13G/A, 2026-11-03 |
The latest filing identifies Pyxis Oncology, Inc. by CUSIP 747324101 and gives its principal executive office as 321 Harrison Avenue, Boston (SCHEDULE 13G/A, 2026-11-03).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-01 | Millennium Management LLC | 5.7% | SCHEDULE 13G |
| 2025-07-17 | BlackRock, Inc. | 1.5% | SCHEDULE 13G/A |
| 2025-09-23 | GordonMD Global Investments LP | 6.2% | SCHEDULE 13G |
| 2025-10-14 | Millennium Management LLC | 1.3% | SCHEDULE 13G/A |
| 2026-02-09 | Laurion Capital Management LP | 7.72% | SCHEDULE 13G/A |
| 2026-07-02 | GordonMD Global Investments LP | 12.1% | SCHEDULE 13G/A |
| 2026-07-10 | Bvf Partners L P | 9.99% | SCHEDULE 13G |
| 2026-10-02 | GordonMD Global Investments LP | 17.5% | SCHEDULE 13G/A |
| 2026-10-05 | Coastlands Capital LP | 5.42% | SCHEDULE 13G |
| 2026-10-09 | GordonMD Global Investments LP | 16.4% | SCHEDULE 13G/A |
| 2026-11-03 | Laurion Capital Management LP | 5.16% | SCHEDULE 13G/A |
Questions about who owns Pyxis Oncology, Inc.
Who owns Pyxis Oncology, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Pyxis Oncology, Inc.: GordonMD Global Investments LP (16.4%, Schedule 13G/A, filed 2026-10-09), Bvf Partners L P (9.99%, Schedule 13G, filed 2026-07-10), Coastlands Capital LP (5.42%, Schedule 13G, filed 2026-10-05) and Laurion Capital Management LP (5.16%, Schedule 13G/A, filed 2026-11-03).
Who are the largest shareholders of Pyxis Oncology, Inc.?
By the share each holder's latest filing reports, the largest holders of Pyxis Oncology, Inc. on this page are GordonMD Global Investments LP (16.4%), Bvf Partners L P (9.99%) and Coastlands Capital LP (5.42%).
When did GordonMD Global Investments LP buy into Pyxis Oncology, Inc.?
The filings give report dates, not purchase dates. The earliest filing from GordonMD Global Investments LP on this page is the Schedule 13G, filed 2025-09-23, reporting 6.2%; its latest, Schedule 13G/A filed 2026-10-09, reports 16.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Pyxis Oncology, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 8, 2026 | Leadership change: Thomas Civik appointed, Chief Executive Officer, and 2 more | — | Leadership changes | Source |
| April 30, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Pyxis Oncology, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.